Article

Placental corticotrophin-releasing hormone and its receptors in human pregnancy and labour: still a scientific enigma.

Endocrinology and Metabolism, Division of Clinical Sciences, Warwick Medical School, University of Warwick, Coventry, UK.
Journal of Neuroendocrinology (Impact Factor: 3.51). 05/2008; 20(4):432-8. DOI: 10.1111/j.1365-2826.2008.01660.x
Source: PubMed

ABSTRACT It is now accepted that, in humans, placental corticotrophin-releasing hormone (CRH) is involved in the mechanisms controlling the onset of labour; however, the precise biological role in foeto-maternal tissues remain enigmatic. Maternal plasma levels of CRH rise exponentially as pregnancy progresses towards term and peak during labour; however, evidence to link this with an active role in the onset and progression of labour, is still inconclusive. Certainly, one of the tissues targeted by CRH is the myometrial smooth muscle, which expresses a plethora of specific CRH receptors. This finding implicates CRH in the mechanisms preparing the myometrial microenvironment for the onset of labour and possibly in the regulation of active contractility during labour. Other gestational tissues also targeted by CRH include the placenta, foetal membranes and foetal adrenals, where CRH might regulate distinct physiological functions, ranging from control of vascular tone to adrenal steroidogenesis and prostaglandin synthesis and activity. Given the unique, among mammals, pattern of human placental CRH secretion and CRH receptor expression and signalling during pregnancy and labour, there are only limited biological tools available to delineate the actions of CRH in foeto-maternal tissues, primarily based on in vitro characterisation of the signalling and molecular events driven by CRH. This review will set in context the current concepts about the role of CRH and its receptors during pregnancy and labour, focusing on the unresolved questions and paradoxes that currently exist.

0 Bookmarks
 · 
85 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background:To identify genetic variants contributing to preterm birth using a linkage candidate gene approach.Methods:We studied 99 single nucleotide polymorphisms for 33 genes in 257 families with preterm births segregating. Nonparametric and parametric analyses were used. Premature infants and mothers of premature infants were defined as affected cases in independent analyses.Results:Analyses with the infant as the case identified two genes with evidence of linkage: CRHR1 (p=0.0012) and CYP2E1 (p=0.0011). Analyses with the mother as the case identified four genes with evidence of linkage: ENPP1 (p=0.003), IGFBP3 (p=0.006), DHCR7 (p=0.009), and TRAF2 (p=0.01). DNA sequence analysis of the coding exons and splice sites for CRHR1 and TRAF2 identified no new likely etiologic variants.Conclusion:These findings suggest the involvement of six genes acting through the infant and/or the mother in the etiology of preterm birth.Pediatric Research (2012); doi:10.1038/pr.2012.166.
    Pediatric Research 11/2012; · 2.67 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction Intrahepatic cholestasis of pregnancy (ICP) is associated with an increased risk of adverse pregnancy outcomes. Fetal distress in ICP is an acute process, and the abnormal expression of placental local vasodilatory factors play an essential role. Urocortin (UCN) exhibits a powerful concentration-dependent vasodilatation effect in the utero-placental-fetal unit. Our study aimed to investigate placental and serum UCN expression in ICP patients. Methods Blood and placenta samples were obtained from the ICP patients and controls. UCN and corticotrophin-releasing hormone receptor-2 (CRH-R2) expression were detected by ELISA, immunohistochemistry, Western Blotting and real-time PCR. Results Placental UCN expression of ICP was lower compare to the controls (0.27±0.11 vs. 0.85±0.21) (P<0.05). Placental CRH-R2 (0.97±0.09 vs. 0.86±0.09) showed no difference between the ICP and controls (P>0.05). Placental UCN mRNA (1.45±0.31 vs. 0.72±0.29) and CRH-R2 mRNA expression (1.11±0.10 vs. 0.84±0.24) were higher compared to the controls (all P<0.05). Maternal serum UCN levels demonstrated no difference from 34 (79.47±11.35 pg/ml) to 37 (84.24±13.62 pg/ml) weeks of gestation in controls (P>0.05). Maternal serum UCN levels of ICP were decreased from 34 (68.53±16.95 pg/ml) to 37 (47.91±15.65 pg/ml) weeks of gestation (P<0.05) and were lower than controls at 35 (64.19±22.50 pg/ml), 36 (50.06±13.98 pg/ml) and 37 weeks of gestation (all P<0.05). Discussion The down-regulated UCN expression in the placenta and maternal serum during ICP may impair the blood flow regulation of the utero-placental-fetal unit and contribute to fetal distress. Maternal serum UCN levels might represent a potential clinical predictor of adverse fetal outcomes and optimize the clinical management.
    Placenta 01/2014; · 3.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: L’activation du système rénine-angiotensine-aldostérone peut entraîner le développement d’une hypertension artérielle et de la fibrose cardiaque. Toutefois, au cours de la grossesse, malgré une hausse substantielle des niveaux d’aldostérone, ces effets délétères ne sont pas observés. L’aldostérone exerce ses effets via les récepteurs des minéralocorticoïdes, les MR, qui peuvent également lier le cortisol avec une affinité similaire. La régulation des niveaux locaux de ce glucocorticoïde par les 11β-hydroxystéroïde déshydrogénases (11β-HSD) est donc essentielle pour éviter une stimulation inappropriée des MR. Nous suggérons que, durant la grossesse, ces enzymes sont impliquées dans la protection de la mère et du foetus contre les niveaux élevés d’aldostérone et de cortisol. Notre hypothèse de travail est que les mécanismes d’adaptation qui prennent place au cours de la grossesse nécessitent des changements d’expression (ARNm et protéine) et d’activité des 11β-HSD spécifiques selon le tissu. Des rates Sprague-Dawley ont été sacrifiées aux jours 14, 17, 19 et 22 de gestation (terme = jour 23) et leurs organes ont été collectés. Dans le rein, les niveaux protéiques des 11β-HSD sont diminués en fin de gestation. Dans le placenta, on observe une importante chute de l’expression génique et protéique de la 11β-HSD1 au jour 17 tandis que la 11β-HSD2 y est augmentée. L’expression et l’activité de la 11β-HSD2 sont par la suite diminuées jusqu’à terme. Aucune différence significative n’est retrouvée dans le ventricule gauche cardiaque. En conclusion, nos résultats démontrent que la gestation est accompagnée d’importants changements dans le placenta, possiblement pour assurer un développement foetal adéquat, tandis que le rein et le coeur sont peu ou pas affectés. Des études plus approfondies sur l’expression des MR dans ces tissus nous aideront à mieux comprendre l’implication des 11β-HSD au fil de la gestation. The activation of the renin-angiotensin-aldosterone system can lead to hypertension and cardiac fibrosis. However, despite a substantial elevation of aldosterone during pregnancy, those adverse effects are not observed. Aldosterone acts via the mineralocorticoid receptors (MR) which can also bind cortisol with a similar affinity. Regulation of the local levels of this glucocorticoid by the 11β-hydroxysteroid dehydrogenases (11β-HSD) is thus crucial to avoid overstimulation of MRs. We believe that these enzymes are involved in the maternal and fetal protections against the high levels of aldosterone and cortisol observed during pregnancy. We propose that the adaptative mechanisms occurring during normal pregnancy involve tissue-specific changes in the expression (mRNA and protein) and activity of both 11β-HSDs. Pregnant Sprague-Dawley rats were sacrified on day 14, 17, 19 or 22 of gestation (term = day 23) and their organs were collected. In the kidney, our results have shown that 11β-HSDs protein levels decrease in late gestation. In the placenta, a dramatic decrease of 11β-HSD1 mRNA and protein expressions is observed on day 17 while 11β-HSD2 levels are increased. Expression and activity of the 11β-HSD2 are then decreased up to day 22. No significant differences were detected in the left cardiac ventricle. In conclusion, our results demonstrate that gestation is associated with important modifications in the placenta, possibly to ensure a normal fetal growth, while expression in the kidney and the heart is barely changed. More studies on MR expression in those tissues will be required to better characterise the function of the 11β-HSDs throughout pregnancy.

Full-text

View
0 Downloads